P P Toth

Summary

Affiliation: Sterling Rock Falls Clinic
Country: USA

Publications

  1. ncbi Colesevelam hydrochloride in the management of dyslipidemia
    Annemarie Armani
    Imprint Science, 230 Park Avenue South New York, NY 10003, USA
    Expert Rev Cardiovasc Ther 4:283-91. 2006
  2. ncbi SPARCL: the glimmer of statins for stroke risk reduction
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 9:347-51. 2007
  3. doi Activation of intracellular signaling systems by high-density lipoproteins
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    J Clin Lipidol 4:376-81. 2010
  4. doi Drug safety evaluation of rosuvastatin
    Peter P Toth
    University of Illinois College of Medicine, CGH Medical Center, Sterling, Peoria, IL, USA
    Expert Opin Drug Saf 10:969-86. 2011
  5. pmc Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
    William Insull
    Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    Vasc Health Risk Manag 6:1065-75. 2010
  6. doi Practical management of anticoagulants in family medicine after orthopedic surgery
    Peter P Toth
    CGH Medical Center, Sterling, IL 61081, USA
    Postgrad Med 124:206-14. 2012
  7. doi Antisense therapy and emerging applications for the management of dyslipidemia
    Peter P Toth
    Department of Preventive Cardiology, CGH Medical Center, Sterling, IL, USA
    J Clin Lipidol 5:441-9. 2011
  8. ncbi Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 11:71-9. 2009
  9. ncbi An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Commentary
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, USA
    J Fam Pract 58:S41-3. 2009
  10. ncbi An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Atherosclerosis: the underlying disease
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, USA
    J Fam Pract 58:S19-25. 2009

Collaborators

Detail Information

Publications49

  1. ncbi Colesevelam hydrochloride in the management of dyslipidemia
    Annemarie Armani
    Imprint Science, 230 Park Avenue South New York, NY 10003, USA
    Expert Rev Cardiovasc Ther 4:283-91. 2006
    ..Colesevelam has a favorable side effect and toxicity profile and significantly impacts serum levels of lipoproteins when used as monotherapy or when used in combination with either statins or ezetimibe...
  2. ncbi SPARCL: the glimmer of statins for stroke risk reduction
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 9:347-51. 2007
    ..Patients with a history of stroke should be treated much more aggressively with statin therapy in order to more optimally reduce risk for stroke recurrence...
  3. doi Activation of intracellular signaling systems by high-density lipoproteins
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    J Clin Lipidol 4:376-81. 2010
    ....
  4. doi Drug safety evaluation of rosuvastatin
    Peter P Toth
    University of Illinois College of Medicine, CGH Medical Center, Sterling, Peoria, IL, USA
    Expert Opin Drug Saf 10:969-86. 2011
    ..Rosuvastatin has been exhaustively evaluated in the setting of a broad variety of dyslipidemias and cardiovascular disease states in clinical trials encompassed within the GALAXY program...
  5. pmc Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
    William Insull
    Baylor College of Medicine and Methodist Hospital, Houston, Texas, USA
    Vasc Health Risk Manag 6:1065-75. 2010
    ....
  6. doi Practical management of anticoagulants in family medicine after orthopedic surgery
    Peter P Toth
    CGH Medical Center, Sterling, IL 61081, USA
    Postgrad Med 124:206-14. 2012
    ..This article examines the clinical evidence for benefits of the new oral anticoagulants, discusses caveats regarding their appropriate use, and provides some guidance regarding bleeding management with these agents...
  7. doi Antisense therapy and emerging applications for the management of dyslipidemia
    Peter P Toth
    Department of Preventive Cardiology, CGH Medical Center, Sterling, IL, USA
    J Clin Lipidol 5:441-9. 2011
    ..One alternative approach, antisense therapy, may offer an effective and well-tolerated option for patients not satisfactorily responsive to or intolerant to standard pharmacologic dyslipidemia therapies...
  8. ncbi Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 11:71-9. 2009
    ..A variety of prospective, placebo-controlled clinical trials have also shown that these agents significantly impact risk for multiple cardiovascular end points...
  9. ncbi An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Commentary
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, USA
    J Fam Pract 58:S41-3. 2009
    ..Unfortunately, for most patients, CHD is not diagnosed during routine screening. Rather, the diagnosis of CHD often is made only after symptoms occur, or when the patient is evaluated incidentally for another health problem...
  10. ncbi An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Atherosclerosis: the underlying disease
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, USA
    J Fam Pract 58:S19-25. 2009
    ..The text and figures that follow will review new developments in our understanding of the pathogenesis of atherosclerosis and new ways that changes in atherosclerotic plaque size and volume can be measured...
  11. ncbi Should we target HDL cholesterol level in lowering cardiovascular risk?
    Peter P Toth
    Preventive Cardiology, Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Pol Arch Med Wewn 119:667-72. 2009
    ....
  12. ncbi Thienopyridine therapy and risk for cardiovascular events in secondary prevention
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Curr Atheroscler Rep 11:364-70. 2009
    ....
  13. pmc Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL, USA
    Cardiovasc Diabetol 8:26. 2009
    ..To evaluate real-world pharmacologic treatment of mixed dyslipidemia in patients with diabetes mellitus (DM)...
  14. doi Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Curr Med Res Opin 25:1355-63. 2009
    ..Niacin and fibrates have been shown in clinical trials to be effective as adjunctive therapy for these lipid abnormalities...
  15. doi Novel therapies for increasing serum levels of HDL
    Peter P Toth
    Sterling Rock Falls Clinic, Ltd, 101 East Miller Road, Sterling, IL 61081, USA
    Endocrinol Metab Clin North Am 38:151-70. 2009
    ..This article discusses the development of newer treatments targeted at raising HDL-C and HDL particle numbers to reduce residual risk in patients at risk for CHD...
  16. doi The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, IL, USA
    Postgrad Med 121:59-72. 2009
    ..Patients with a history of transient ischemic attack or stroke should not receive prasugrel + aspirin because of increased risk of events...
  17. ncbi Review of the AMADEO Study: Reducing Proteinuria in Patients with Diabetic Nephropathy with Telmisartan Versus Losartan
    Peter P Toth
    Sterling Rock Falls Clinic Ltd, CGH Medical Center, Sterling, IL, 61081, USA
    Postgrad Med 122:165-8. 2010
    ..Kidney Int. 2008;74(3):364-369. PRACTICE PEARL: A telmisartan-based regimen showed a greater antiproteinuric effect than a losartan-based regimen at similarly achieved BP levels...
  18. doi Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Expert Rev Cardiovasc Ther 8:425-38. 2010
    ..In addition to substantially inhibiting Lp-PLA(2), darapladib reduces the progression of the necrotic core volume of coronary artery atheromatous plaque...
  19. doi CETP Inhibition: does the future look promising?
    Peter P Toth
    Director of Preventive Cardiology, Sterling Rock Falls Clinic, IL 61081, USA
    Curr Cardiol Rep 13:559-65. 2011
    ....
  20. doi Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Postgrad Med 123:46-53. 2011
    ..6% to 0.8%, with a safety profile comparable with placebo. This article provides a review of linagliptin clinical data for primary care physicians treating patients with type 2 diabetes mellitus...
  21. doi Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy
    Peter P Toth
    Department of Preventive Cardiology, Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    J Clin Hypertens (Greenwich) 13:42-51. 2011
    ..This review also identifies some potentially important differences in the mechanism of action between ARBs and angiotensin-converting enzyme inhibitors that may have clinical significance in the management of vascular diseases...
  22. doi High-density lipoproteins: marker of cardiovascular risk and therapeutic target
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    J Clin Lipidol 4:359-64. 2010
    ..These drugs exploit a diverse range of mechanisms with potential for beneficially impacting the development and progression of atherosclerotic disease...
  23. doi Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Cardiol Rep 12:481-7. 2010
    ....
  24. doi Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 12:331-5. 2010
    ..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial suggests that the addition of fenofibrate to ongoing statin therapy in patients with type 2 diabetes mellitus offers limited benefit...
  25. doi Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs
    Peter P Toth
    Preventive Cardiology, Sterling Rock Falls Clinic, Sterling, Illinois 61081, USA
    Drugs 70:1363-79. 2010
    ..Fibrates, niacin and omega-3 fish oils are efficacious therapies for reducing serum triglycerides. Combinations of these drugs are frequently required for normalizing mixed forms of dyslipidaemia...
  26. ncbi When high is low: raising low levels of high-density lipoprotein cholesterol
    Peter P Toth
    Preventive Cardiology, Sterling Rock Falls Clinic, Ltd, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Cardiol Rep 10:488-96. 2008
    ....
  27. doi Clinical characterization and molecular mechanisms of statin myopathy
    Peter P Toth
    Sterling Rock Falls Clinic, Ltd, 101 East Miller Road, Sterling, IL 61081, USA
    Expert Rev Cardiovasc Ther 6:955-69. 2008
    ....
  28. ncbi High-density lipoprotein and cardiovascular risk
    Peter P Toth
    Sterling Rock Falls Clinic, 101 E Miller Rd, Sterling, Ill, USA
    Circulation 109:1809-12. 2004
  29. ncbi Therapeutic interventions targeted at the augmentation of reverse cholesterol transport
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, Illinois 61081, USA
    Curr Opin Cardiol 19:374-9. 2004
    ..This review summarizes the pathway of RCT and the currently available means by which investigators are attempting to modulate HDL levels and increase rates of RCT...
  30. ncbi Low-density lipoprotein reduction in high-risk patients: how low do you go?
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 6:348-52. 2004
    ....
  31. ncbi Cardiology patient page. The "good cholesterol": high-density lipoprotein
    Peter P Toth
    University of Illinois School of Medicine, Peoria, USA
    Circulation 111:e89-91. 2005
  32. ncbi Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, Illinois, USA
    Expert Opin Pharmacother 6:131-9. 2005
    ..This combination increases the likelihood of therapeutic success in patients with dyslipidaemia...
  33. ncbi New insights in the treatment of dyslipidemia: a focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatin
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Curr Atheroscler Rep 7:335-43. 2005
    ..Additional studies with atorvastatin are underway to further explore the extent to which statins can provide cardiovascular benefits...
  34. ncbi High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, Illinois 61081 1252, USA
    Am J Cardiol 96:50K-58K; discussion 34K-35K. 2005
    ....
  35. ncbi Cholesterol absorption blockade with ezetimibe
    Peter P Toth
    Director of Preventive Cardiology, Sterling Rock Falls Clinic, Illinois, University of Illnois School of Medicine, Peoria, 61081, USA
    Curr Drug Targets Cardiovasc Haematol Disord 5:455-62. 2005
    ..Ezetimibe is indicated in the management of hyperlipidemia, familial hypercholesterolemia, and sitosterolemia and significantly increases the percentage of patients able to reach their lipid-lowering goals...
  36. pmc Subclinical atherosclerosis: what it is, what it means and what we can do about it
    P P Toth
    Sterling Rock Falls Clinic, Sterling, and University of Illinois College of Medicine, Peoria, IL 61008, USA
    Int J Clin Pract 62:1246-54. 2008
    ....
  37. ncbi Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 9:81-8. 2007
    ..Combining new HDL cholesterol-elevating agents with existing LDL cholesterol-lowering agents may improve the cardiovascular risk reductions currently attainable...
  38. ncbi Expert commentary: gastrointestinally active lipid-lowering drug safety
    Peter P Toth
    Sterling Rock Falls Clinic, Ltd, Sterling, Illinois 61081, USA
    Am J Cardiol 99:56C-58C. 2007
  39. doi Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective
    P P Toth
    Preventive Cardiology, Sterling Rock Falls Clinic, Ltd, Sterling, IL 61081, USA
    Int J Clin Pract 63:903-11. 2009
    ..Fenofibrate represents a useful treatment option for controlling cardiovascular risk in type 2 diabetes patients in the community setting...
  40. ncbi Gender differences in adhering to national guidelines in a community lipid clinic
    Nicolas W Shammas
    Midwest Cardiovascular Research Foundation, Cardiovascular Medicine, Davenport, IA 52803, USA
    Prev Cardiol 9:215-8. 2006
    ..A possible gender-independent survivorship effect exists for low-density lipoprotein and high-density lipoprotein...
  41. ncbi Reverse cholesterol transport: high-density lipoprotein's magnificent mile
    Peter P Toth
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 5:386-93. 2003
  42. ncbi Combination therapy in the management of complex dyslipidemias
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA
    Curr Opin Lipidol 15:423-31. 2004
    ..This review discusses the need for comprehensive management of all abnormalities in a given patient's lipoprotein profile and for the use of combinations of anti-lipidemic medications, when indicated...
  43. ncbi Comparative effects of lipid-lowering therapies
    Michael H Davidson
    Radiant Research, Rush Medical College, Rush University Medical Center, Chicago, IL 60602, USA
    Prog Cardiovasc Dis 47:73-104. 2004
    ..This trend portends an ever-growing need for the aggressive and judicious use of different antilipidemic medication(s) in patients at risk for all forms of atherosclerotic vascular disease...
  44. ncbi C-reactive protein and risk of cardiovascular disease: evidence and clinical application
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Curr Atheroscler Rep 5:341-9. 2003
  45. ncbi The CARDS trial: diabetic patients dealt a winning hand
    Annemarie Armani
    Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
    Curr Atheroscler Rep 8:429-32. 2006
    ..Benefit emerged within 1 year of initiating therapy...
  46. ncbi Adiponectin and high-density lipoprotein: a metabolic association through thick and thin
    Peter P Toth
    Eur Heart J 26:1579-81. 2005
  47. ncbi Elevated levels of homocysteine predict cardiovascular death, nonfatal myocardial infarction, and symptomatic bypass graft disease at 2-year follow-up following coronary artery bypass surgery
    Nicolas W Shammas
    Midwest Cardiovascular Research Foundation, Davenport, IA 52803, USA
    Prev Cardiol 11:95-9. 2008
    ..Logistic regression analysis modeling for low-density lipoprotein cholesterol, lipoprotein(a), fibrinogen, and homocysteine showed that homocysteine value (P=.016) was an independent predictor of the primary combined end point...
  48. ncbi High-dose statin therapy: benefits and safety in aggressive lipid lowering
    Peter P Toth
    Department of Family and Community Medicine, University of Illinois School of Medicine, Peoria, Illinois, USA
    J Fam Pract 57:S29-36. 2008
  49. ncbi High-density lipoprotein metabolism: potential therapeutic targets
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 100:n32-40. 2007
    ....